ホーム>>Signaling Pathways>> Neuroscience>> Amyloid β>>Ro 90-7501

Ro 90-7501

カタログ番号GC10425

Ro 90-7501 は、アミロイド β42 (Aβ42) 原線維集合阻害剤であり、Aβ42 による細胞毒性 (EC50 2 μM) を低減します。

Products are for research use only. Not for human use. We do not sell to patients.

Ro 90-7501 化学構造

Cas No.: 293762-45-5

サイズ 価格 在庫数 個数
5mg
$128.00
在庫あり
10mg
$241.00
在庫あり
25mg
$565.00
在庫あり
50mg
$1,004.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ro 90-7501 is a bi-benzimidazole compound that was first found to retard the formation of mature amyloid β42 fibrils in a cell-based assay.[1] Instead, extended polymeric sheets and fibrillary intermediates of amyloid β42 accumulated in response to Ro 90-7501 treatment, resulting in reduced cytotoxicity (EC50 = 2 µM).1 More recently, Ro 90-7501 was shown to modulate signaling in cells stimulated with polyinosinic-polycytidylic acid (poly(I:C); a toll-like receptor 3 (TLR3), and RIG-1-like receptor agonist.[2] Ro 90-7501 (10 µM) enhanced poly(I:C)-induced IFN-β expression, decreased NF-κB activation, and amplified the suppression of vesiculastomatitis virus replication by poly(I:C) in HEK293 cells expressing TLR3.[2]

Reference
[1]. Bohrmann, B., Adrian, M., Dubochet, J., et al. Self-assembly ofβamyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. Journal of Structural Biology 130(2-3), 232-246 (2000).
[2]. Guo, F., Mead, J., Aliya, N., et al. RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response. PLoS One 7(10), (2012).

レビュー

Review for Ro 90-7501

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ro 90-7501

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.